Recent studies have found that the combination of glutamine metabolism blockade and anti-PD-1 immunotherapy will not only inhibit the metabolism of tumor cells but also promotes glucose metabolism, epigenetic reprogramming, and cytotoxic function in T cells to improve the antitumor effect of immune cells [116]. The gene discussed is PDCD1; the disease is neoplasm.